Debut and DIC Corporation announced an agreement to biomanufacturing and sell a large number of sustainably produced, rare, and natural polyphenol ingredients. This strategic partnership brings novel, high-performing, and clinically backed polyphenols to consumers for the first time and opens new product possibilities and health benefits for brands and consumers globally. Tiny amounts of these bioactive compounds can be found in fruits, vegetables, and nature, but their rarity makes these compounds too expensive or environmentally unsustainable for use in consumer products, despite their enhanced clinically proven benefits.

This multiyear agreement focuses on bringing such rare naturals made possible through Debut's Bio2Consumer(TM) platform. The agreement will deliver rare and natural cosmetic ingredients concurrent with the construction of a commercial biomanufacturing facility slated to come online in 2024. As part of the agreement, Debut will build a commercial biomanufacturing site, with construction beginning in the coming months.

The site will be owned and operated by Debut, alleviating global biomanufacturing constraints while proving the operational flexibility to produce a wide variety of ingredients. This biomanufacturing site will allow the company to realize its goals of delivering new cosmetic ingredients with revolutionary capabilities to the beauty industry. DIC, whose customers include brand owners that prioritize safety, efficacy and sustainability, will lead ingredient sales, marketing, and distribution of these ingredients globally.

DIC shares Debut's commitment to sustainable manufacturing and is a fine chemical company with a top share of the global market for printing inks, organic pigments, and other other compounds. In recent years, the company has affirmed a strong commitment to creating new businesses that respond to environmental, social and health (ESH)-related issues and social changes.